Catalyst Funds Management
SABS icon

Catalyst Funds Management’s SAB Biotherapeutics SABS Stock Holding History

Catalyst Funds Management’s Portfolio SABS Stock Details SABS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-15,100
Closed -$57.8K – 855
2026
Q1 		$57.8K Buy
+15,100
New +$60.2K 0.01% 531

Other funds holding SABS

Caligan Partners
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
Vivo Capital
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Perceptive Advisors
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
RA Capital Management
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Commodore Capital
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Catalyst Funds Management's SABS Position: Q2 2026 in Review

Catalyst Funds Management sold out of SAB Biotherapeutics (SABS) in Q2 2026, closing a stake of 15,100 shares — an estimated $57.8K sold.

Catalyst Funds Management first reported a position in SABS in Q1 2026 and held it in 1 quarter. The position peaked at $57.8K in Q1 2026. 87 funds tracked by Wall St. Rank hold SABS as of Q2 2026.

  • Catalyst Funds Management reported no remaining SAB Biotherapeutics position as of Q2 2026 after selling out during the quarter.
  • Catalyst Funds Management sold 15,100 SAB Biotherapeutics shares in Q2 2026, an estimated $57.8K.
  • Catalyst Funds Management first reported a position in SAB Biotherapeutics in Q1 2026 and held it in 1 quarter.
  • Catalyst Funds Management's SAB Biotherapeutics position peaked at $57.8K in Q1 2026.
  • 87 funds tracked by Wall St. Rank held SAB Biotherapeutics as of Q2 2026.

Based on Catalyst Funds Management's 13F filing for Q2 2026, filed 10 Aug 2026.